In this episode, David interviews psychiatrist, main researcher behind the first US Phase II trial of MDMA-assisted psychotherapy, and Senior Medical Director at MAPS Public Benefit Corporation: Dr. Michael Mithoefer; and Research Group Lead at the University of Zurich, and Principal Clinical Biomarker Lead at Boehringer Ingelheim, Katrin Preller, Ph.D. Mithoefer, Preller (and David) are speakers at the upcoming Psychedelic Medicine – Israel, which will now take place July 28 - 31, 2024, in Tel Aviv. They discuss the conference and their current research: Preller's neuroimaging and work with psilocybin for alcohol use disorder, and Mithoefer (likely) being extremely close to seeing the FDA approve MDMA-assisted psychotherapy. He talks about how the therapeutic protocols for MDMA-assisted psychotherapy were created, what it's like to be so close to legalization, and how the next challenges will be accessibility and not minimizing therapy in favor of faster turnover.  They discuss neuroplasticity and whether or not it actually translates into something in humans; the concept of performing brain scans before a psychedelic experience to look for trauma biomarkers (and how this could actually result in savings over time); the excitement of seeing clinical work and neuroscience progressing in parallel; why integration frameworks need to be individualized; and the importance of embracing different therapeutic approaches. Click here to head to the show notes page.

In this episode, Melanie Pincus, Ph.D. and Manesh Girn, Ph.D. once again take over hosting duties, this time interviewing Gül Dölen, MD, Ph.D.: Associate professor of Neuroscience and Neurology at the Johns Hopkins University, School of Medicine, and head of the Dölen lab. Dölen largely researches the neuroscience behind social behaviors and is most known for her work in establishing how psychedelics reopen critical periods of learning, and that the true benefit of psychedelics could be in learning how best to reopen those critical periods, how long they’re open for, and which therapeutic frameworks and integration practices could best take advantage of them. Her most recent research was giving MDMA to otherwise very asocial (and violent) octopuses to prove that a drastically different species would exhibit typical MDMA-inspired prosocial behavior. And, after discovering that all the classic psychedelics worked to reopen critical periods – that psychedelics are apparently the master key to opening these periods – she’s now researching why, through the PHATHOM project (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability). You will likely learn a ton in this episode: why critical periods close as we get older and what may impede them from opening more often; how plasticity and metaplasticity relate to each other and why increased neuroplasticity isn’t always a good thing; how the length of different psychedelic experiences relates to efficacy; why the different results of MAPS’ and Compass Pathways’ studies show the importance of therapy; how autism could be related to critical periods; why repeated psychedelic use may make it harder for one’s brain to reset; and how important context is in the ability to reopen critical periods – especially around social learning. Click here to head to the show notes page. 

In this episode, Joe interviews Federico Seragnoli: coordinator of the ALPS Foundation, psychologist who works with patients undergoing compassionate use treatments with psychedelics, and Founder of the ALPS Conference. This year, the ALPS Conference (which stands for Awareness Lectures on Psychedelic Science) takes place Oct. 27 – 29 at the Bâtiment des Forces Motrices in Geneva – a prime location for a conference due to Switzerland’s legality around psychedelics, where any citizen can apply for psilocybin or LSD therapy if they fall into the category of ‘treatment-resistant.’ Seragnoli discusses how the conference was originally inspired by an article on the MAPS blog about how to be a psychedelic researcher; and talks about its humble beginnings, its new location, and why it’s moved across the country each year. The conference features names like Rick Doblin and Michael Mithoefer, but he’s most excited about the smaller size of the event and the panel discussions, which gives attendees a chance to ask questions and hear some real conversations.  He discusses the vibrant field of psychedelic therapy and research in Switzerland; the importance of compassionate use and the criteria physicians need to be able to use it; the impact of students creating psychedelic associations at their universities; and Seragnoli’s new research: seeing if there is a link between cognitive science and a conceptualization of science – if you can model consciousness off neuroscience, can you model it off how you feel? Click here to head to the show notes page. 

Jungian analyst-in-training and clinician discuss the connection between dreams and psychedelics, exploring Jungian psychology, nature's equilibrium, and reclaiming aliveness. The conversation dives into symbolism, working with dreams to guide experiences, and the clash between conscious and unconscious realms.

Louie Schwartzberg, renowned filmmaker known for the award-winning documentary 'Fantastic Fungi' and director of 'Gratitude Revealed,' discusses how psychedelics inspired his cinematic exploration of the invisible. He talks about his techniques to capture the unseen aspects of reality, the premiere of 'Fantastic Fungi,' his new streaming channel, and a clinical trial on using imagery and music on psilocybin. He also explores the power of gratitude, resilience, and the blessing of being a photographer.

Joe interviews Deborah C. Mash, Ph.D., leading researcher in addiction and brain disorders. She talks about ibogaine research challenges, the need for partnerships, and collecting Phase II and III data. Also discusses her study on Cocaethylene, deaths related to iboga, and the French use of noribogaine. Deb Mash shares her experience at a psychedelics science event and highlights the potential of Ibogaine for addiction treatment. Talks about the risks and challenges of using Ibogaine, conservation efforts within the indigenous community, and the challenges of implementing an ibogaine initiative.

In this episode, David interviews Madison Margolin: NY-based, psychedelics and Judaism-focused journalist; host of the Set & Setting podcast; co-founder of DoubleBlind Magazine and the Jewish Psychedelic Summit; and author of the soon-to-be released, Exile & Ecstasy: Growing Up With Ram Dass and Coming of Age in the Jewish Psychedelic Underground. They explore the relationship between Judaism and psychedelics, with Margolin sharing her experiences growing up in a Hindu-Jewish family; her personal journey with her Jewish identity; and how her use of psychedelics has deepened her life. She talks about the significance of Jewish holidays, and how holiday traditions connect them to nature and themselves in a very psychedelic way; the importance of intentionality; the beauty in dancing through an uncomfortable ayahuasca experience; the Jewish Psychedelic Summit; whether or not ancestors were using substances (and does that matter?), and why being in Israel feels so different – and psychedelic.  Margolin is an instructor in our new course, “Navigating Psychedelics: Jewish Informed Perspectives,” where she will be leading discussions on setting sacred time and space, particularly focusing on the significance of Shabbat and the energetic frequencies that are at play during certain holidays. The 9-week course begins next week – October 10 – so sign up now!  Click here to head to the show notes page. 

In this episode – with the ​2024 edition of Vital​ announced and applications officially open – we’re launching another series of Vital Psychedelic Conversations, with David hosting Jasmine Virdi: Vital instructor, writer, educator, and activist who works at Synergetic Press and volunteers for Fireside Project; and Tabata Gerk: Vital student, psychotherapist, and facilitator. As always, they discuss what they think the most vital conversation should be right now, largely expressing concerns over the medicalization of psychedelics and the idea of a ‘traumadelic culture,’ where psychedelics are often only seen as healers of trauma and not doorways to mysticism and new ideas. And they point out another concern: the romanization of Indigenous culture and not recognizing that these are contemporary cultures that are affected by the same Western, capitalist paradigms that affect us all. They also discuss the concept of epistemic injustice and needing to respect other ways of knowing; hyper-individualism and why we became so reductionist as a society; the role of money (who defines the problem and the solution?); concerns over who decides who is allowed to use these substances; the power of small steps of change; and, through talking about Gerk’s recent Amazonian ayahuasca experience, they dig into what it is about these experiences and surrounding communities that make them so special. Could we take some of that and effectively incorporate it into our Western models? Click here to head to the show notes page. 

In this episode, Joe interviews Ethan Nadelmann: author, speaker, Founder and former Executive Director of Drug Policy Alliance, host of the PSYCHOACTIVE podcast, and one of the leading voices in drug policy reform and harm reduction.  Nadelmann shares his journey from Princeton University to founding Drug Policy Alliance, to working with George Soros, encouraging Gary Johnson to push cannabis legalization, and interacting with prominent figures like Milton Friedman and Grover Norquist. He explores the motivations behind the drug war, the massive growth of incarcerations it led to, why the US spread its war on drugs abroad even when it went against our best interests, and, thankfully, the progress made in fighting the drug war – particularly with cannabis and psychedelics. And he discusses much more: the banning of drug testing kits; the damages of our slow learning curve against the idea of a safe supply; the risks of under-prescribing opioids for people who actually need them; how libertarians, the right, and left are all starting to become against the drug war for the same reasons; why cigarette smokers should all switch to vaping; the concept of needing to pass a test at the pharmacy to prove you understand (and won't abuse) medication; and some strong arguments for decriminalization as an incremental step. And he asks some pretty important questions that we can all simmer on for a bit: how do we find a balance between helping people and not opening the rest of society up to harm? How do we challenge abuse in a way that doesn't hurt future harm reduction efforts? And how do we incentivize people into acting in their own best interests?  Click here to head to the show notes page. 

In this special episode, Melanie Pincus, Ph.D. and Manesh Girn, Ph.D., who joined David in episode 403 to discuss the launch of their new course, essentially interview each other. As the 2nd edition of their popular course, Psychedelic Neuroscience Demystified, begins on November 1, we wanted to give them a chance to highlight some of the aspects of neuroscience students can expect to learn in the course, and what so many people who are interested in psychedelics don’t fully understand: What does neuroplasticity actually entail? Can one predict if a patient is more apt to have an experience with ego dissolution? How does the amygdala relate to mood disorders? When are critical periods of greater plasticity and socialization at their most beneficial? How does neuroplasticity relate to chronic stress? They also discuss lessons they’ve received from their own journeys; why they created the course; serotonin; psychological flexibility; body-based versions of self vs. memory-based versions; psychedelics and re-encoding memories (and the potential for false memories); how psychedelic therapy is different from standard drug treatments; psychedelics and the default mode network (is the story oversimplified?), and much more.  Click here to head to the show notes page.